Thymosin Alpha-1

What is Thymosin Alpha-1?

Thymosin Alpha-1 is a 28-amino-acid peptide that is naturally produced by the thymus gland. It plays a central role in immune system maturation and regulation. The synthetic version (Zadaxin/Thymalfasin) is approved in over 35 countries for the treatment of hepatitis B and C, and as a vaccine adjuvant. It is not FDA-approved in the United States but is available through compounding pharmacies.

What Thymosin Alpha-1 Is Investigated For

Thymosin Alpha-1 is investigated for chronic hepatitis B and C, vaccine response enhancement in immunocompromised populations, severe sepsis, acute pancreatitis, and more recently for COVID-19 and post-viral immune restoration. The strongest evidence is in chronic hepatitis B and C — the basis for its approval as Zadaxin/thymalfasin in over 35 countries — with a deep meta-analysis literature supporting its use as an adjunct to interferon and nucleoside analog therapy, plus solid RCT data in severe sepsis and acute pancreatitis. The honest caveats are genuinely regulatory rather than safety-based. Thymosin Alpha-1 has never been FDA-approved in the US despite decades of international approvals, and in 2023 the FDA removed it from the 503A compounding bulk substances list based on size-and-complexity risk criteria (not a specific harm signal), materially narrowing legitimate US access. Long COVID data is observational rather than RCT-level, the 'general immune booster' framing overstates the evidence — strongest support is in specific dysregulated-immunity contexts — and research-chemical supply is not equivalent to pharmaceutical Zadaxin. Thymosin Alpha-1 should not be confused with Thymosin Beta-4 (TB-500), which is a different peptide family entirely.

History & Discovery

Thymosin Alpha-1 was isolated in the 1970s by Allan Goldstein and colleagues at the Albert Einstein College of Medicine, working from the thymosin fraction 5 preparation originally extracted from calf thymus in the 1960s. The 28-amino-acid sequence (corresponding to the N-terminus of prothymosin alpha) was characterized as the principal immunologically active component and, shortly after, produced synthetically. Goldstein went on to co-found SciClone Pharmaceuticals, which commercialized the synthetic peptide as Zadaxin (thymalfasin) for hepatitis B, hepatitis C adjunct therapy, and immune reconstitution. Over the following decades Zadaxin was approved in more than 30 countries — including Italy, China, Egypt, the Philippines, and much of Asia and Latin America — primarily for chronic hepatitis B and C and for use as a vaccine adjuvant in immunocompromised populations. It was never approved by the US FDA, despite multiple attempted indications, and remained available domestically only through compounding pharmacies. During the early COVID-19 pandemic, Italian and Chinese clinicians used Tα1 off-label in severe cases and published preliminary observational data that generated significant interest, though no large randomized trial produced a definitive result. In late 2023, the FDA removed Thymosin Alpha-1 from the 503A compounding bulk substances list following its risk-based review, materially narrowing US clinical access.

How It Works

Thymosin Alpha-1 helps train and regulate your immune system. It supports the maturation of T-cells (key immune fighters) and helps balance the immune response — boosting it when needed and calming it when overactive.

Thymosin Alpha-1 acts on toll-like receptors (TLR2, TLR9) on dendritic cells, promoting their maturation and antigen presentation. It enhances T-cell differentiation and function, increases NK cell activity, and modulates cytokine production. It promotes Th1 responses while modulating excessive inflammatory responses. It also enhances the expression of MHC class I molecules, improving immune surveillance.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Thymosin Alpha-1:

• 01US regulatory pathway — despite three decades of international approvals, Tα1 has never completed the US trial program that would support FDA approval, and the evidence base consists mostly of non-US trials with varying methodology.
• 02Long-COVID efficacy — the 2023 observational data showing restored T-cell homeostasis is mechanistically interesting but has not been replicated in a large randomized controlled trial.
• 03Optimal duration for immune-support indications — approved protocols run 6 months for hepatitis, but off-label immune-modulation durations are largely clinician preference without dose-duration-response data.
• 04Head-to-head comparisons with other immune modulators — there is little rigorous comparison between Tα1 and alternatives like low-dose naltrexone, thymic extracts, or interferon in non-hepatitis indications.
• 05Long-term safety beyond 12 months of continuous use — most trials cap at 6–12 months; indefinite use data is absent.
• 06Biomarker-guided dosing — whether baseline T-cell subsets, NK activity, or inflammatory markers predict response to Tα1 has not been prospectively validated.

Forms & Administration

Thymosin Alpha-1 is administered via subcutaneous injection. International prescribing guidelines exist for approved indications. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Thymosin Alpha-1 is approved internationally but not FDA-approved in the United States. Any use should be under the direct supervision of a qualified healthcare provider who can evaluate individual risk factors and verify product sourcing.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Thymosin Alpha-1 Is NOT For

Drug & Supplement Interactions

Formal human drug-interaction studies for Tα1 are limited, and most interaction information derives from its use alongside antivirals and immunomodulators in hepatitis and sepsis trials rather than from dedicated pharmacokinetic work. The most clinically relevant co-administration is with antiviral therapy for hepatitis B and C — pegylated interferon, entecavir, and historically ribavirin — where Tα1 is positioned as an adjunct that enhances virologic response without meaningful pharmacokinetic interference. This pairing has been the subject of multiple randomized trials and is reflected in international prescribing information. Tα1 has also been combined with ulinastatin in sepsis protocols and with standard vaccine regimens as an adjuvant, again without reported pharmacokinetic interaction. Theoretical concerns apply in the opposite direction: patients on clinically meaningful immunosuppression (post-transplant regimens, high-dose corticosteroids, calcineurin inhibitors, biologic immunosuppressants) could plausibly see reduced efficacy of their immunosuppressive agents or altered immune balance, and co-administration should be managed by the prescribing specialist rather than introduced informally. Patients on any regular medication should disclose Tα1 use to their full care team.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions